Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.
about
Abiraterone in metastatic prostate cancer without previous chemotherapyEvidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancerA review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patientsTargeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer.Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinasesPosttranslational modification of the androgen receptor in prostate cancer.Enhanced cytotoxicity from deoxyguanosine-enriched T-oligo in prostate cancer cells.Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation.Update in systemic therapy of urologic malignancies.Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors.PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).Real-time monitoring of tumor progression and drug responses in a preclinical mouse model of prostate cancerProstate cancer incidence and survival in immigrants to Sweden.
P2860
Q24612084-EA5755DF-D560-4A9D-8635-2FBDC6B58D13Q26739738-0ED4C7B1-3C27-4D26-AF76-ECE961E293F1Q28076622-DC7A5E62-CACD-4D86-B975-BE7BCA91101DQ34101055-79951740-462D-4E40-8D36-83B335F26F30Q34289164-18C5EF3E-9FF4-4836-9BDC-027526B46641Q35749794-2C1E3E21-ABEC-4950-91DA-FB54EFACDCACQ37092022-EFE16C50-00DB-430E-B818-7E174C84F735Q37139643-2F248FC2-8E36-4F4A-A7CD-01CA8665CA64Q37236912-7D1A670E-61E8-437F-9186-99BE94EF1CB8Q38176143-FBF3284A-41D0-4AA2-9633-6AD5DDD37C30Q38612952-6E33FB44-E5FF-47B1-9916-CA6993EA2E95Q38825075-95C02822-40EE-4131-89DB-9C84F41B6104Q40239582-BBF28AEB-9064-4BCB-8621-BFDDECE64C08Q41561800-C603F614-39FC-45B4-AAE1-3E7BBEE021E8Q44766588-4EDFD5F1-348A-4156-8874-3CF95F705B61
P2860
Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Castration-resistant prostate ...... ptions, many challenges ahead.
@en
Castration-resistant prostate ...... ptions, many challenges ahead.
@nl
type
label
Castration-resistant prostate ...... ptions, many challenges ahead.
@en
Castration-resistant prostate ...... ptions, many challenges ahead.
@nl
prefLabel
Castration-resistant prostate ...... ptions, many challenges ahead.
@en
Castration-resistant prostate ...... ptions, many challenges ahead.
@nl
P2860
P356
P1433
P1476
Castration-resistant prostate ...... ptions, many challenges ahead.
@en
P2093
Brian I Rini
Jorge A Garcia
P2860
P304
P356
10.1002/CNCR.26582
P407
P577
2011-10-28T00:00:00Z